Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Change in Inventory (2016 - 2023)

Lexaria Bioscience's Change in Inventory history spans 9 years, with the latest figure at -$76782.0 for Q2 2023.

  • Quarterly results put Change in Inventory at -$76782.0 for Q2 2023, down 641.35% from a year ago — trailing twelve months through Feb 2024 was -$76782.0 (down 351.14% YoY), and the annual figure for FY2023 was -$43069.0, down 2076.3%.
  • Change in Inventory for Q2 2023 was -$76782.0 at Lexaria Bioscience, down from $64504.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $80257.0 in Q2 2019 to a low of -$88859.0 in Q2 2021.
  • The 5-year median for Change in Inventory is -$5782.0 (2019), against an average of -$6553.4.
  • The sharpest move saw Change in Inventory crashed 956.66% in 2022, then surged 1482.92% in 2023.
  • Year by year, Change in Inventory stood at $6160.0 in 2019, then fell by 1.51% to $6067.0 in 2020, then plummeted by 148.03% to -$2914.0 in 2021, then crashed by 956.66% to -$30791.0 in 2022, then plummeted by 149.37% to -$76782.0 in 2023.
  • According to Business Quant data, Change in Inventory over the past three periods came in at -$76782.0, $64504.0, and -$30791.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.